Chairman of the Board
Mr. Blondel is Co-Founder and Chairman of the Board of KiOmed Pharma.
As an entrepreneur, he has acquired a broad experience in the management and the development of innovation driven companies. Having graduated in both Law and Economics, nowadays he combines executive functions (as CEO of KitoZyme) with non-executive board memberships, either as Chairman of the Board or as an Board member. The companies in which he is active range from major listed companies, such as RECTICEL (an industrial multinational group) to SMEs, spin-offs and research centers, such as NANOCYL (a world leader in the production of carbon nanotubes), OncoDNA, OVIZIO Imaging Systems, which are active in the technology, medical or healthcare sectors.
Mr. Blondel started his career in the chemical sector and undertook assignments both in the United States and in Europe. In 1999, he joined International Brachytherapy (IBt), a medical device start-up that focused on cancer treatment. He served as CEO, leading IBt, now a Euronext stock listed company, from its R&D stage to a successful and well-diversified international group that became a European leader in its market segment.
Mrs. Leblanc is Director of KiOmed Pharma.
Françoise Leblanc is managing partner at Spin Venture (Meusinvest group). She has several non-executive memberships in Biotech spin-off and SME actives in healthcare and industrial business.
Mr. Nolet is Director of KiOmed Pharma.
Marc Nolet de Brauwere obtained his Master’s degree as a Mining Civil Engineer from the Catholic University of Louvain (UCL) in 1982, then specialized as a Civil Engineer in Industrial Management at the Katholiek Universiteit Leuven (KUL) in 1983. He started his career in 1984, as Manager of the Engineering department at Petrofina (Kentucky Prince Coal Corporation). In 1978, he also took charge of the development of a downstream activity (gold mining) at Chemetech Corporation. He served for these two companies until 1989, then moved on to McKinsey & Company, as an Associate.
In 1992, Marc created Dat International SA with an ex-colleague of McKinsey, and set up a distribution network specialized in supply parts from the EEC to local companies in East Africa. Finally, in 1997, he became CEO of Physiol SA. Besides, he was nominated Director at ETEX group in 2003, where he served as chairman of the Audit committee from 2006 to 2013. He became Chairman of the Nominations and Remunerations Committee in 2013. In addition, he became Director of Mecatech (2011), Biotech Coaching (2011), MyMicroInvest (2013) and EndoTools Therapeutics (2013). Since 2011 he also is a member of Ashoka Support Network since 2011.
Mr. Lefebvre is Director of KiOmed Pharma.
He is Investment Manager at SRIW SA. He has several non-executive memberships in biotech spin-off and SME active in the life science and industrial business.
In 1995, Géry Lefebvre graduated in Business Administration from HEC-ULg and started immediately his career in Credit Management with Atradius and HSBC. In 2002, he obtained a post-graduate degree in Taxation from HEC-ULg. After that he moved to Albemarle Europe where he was responsible for Treasury Management and Working Capital Optimization. Between 2009 and 2014, he was the CFO of Belgian Advanced Technology Systems SA (Homeland Security).
Dr Houtaï CHOUMANE
CEO & Managing Director
Dr. Choumane has been both CEO and Managing Director of KiOmed Pharma since March 2014.
He has acquired a broad experience in the management and business development of innovative biotech companies. He has a highly diverse background that combines a technical element (he holds a PhD in Sciences) and business administration (he received an Executive MBA from HEC-Paris), as well as a Major in Innovation and Entrepreneurship from Babson College (MA, USA).
He served as COO for KiOmed Pharma from its inception in 2012 up to March 2014, where he was appointed both CEO and Managing Director. Dr. Choumane acquired experience in joint health markets as the CEO of Artialis S.A, a first-mover biotech company that specialized in the development and the clinical applications of biomarkers for the diagnosis and prognosis of musculoskeletal disorders. As CEO, he drove and accelerated value creation at Genewave S.A, a development-stage diagnostics company that specialized in hospital-acquired infections, which capitalized on its innovation and R&D.
Dr. Choumane started his carrier as R&D project manager at the European Commission and Genewave S.A. It was at Genewave where he developed and patented innovative technologies for life science and medical diagnostics.